XSHE
002728
Market cap762mUSD
Oct 09, Last price
10.24CNY
1D
3.02%
1Q
7.11%
Jan 2017
-46.56%
IPO
29.29%
Name
Teyi Pharmaceutical Group Co Ltd
Chart & performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Teyi Pharmaceutical Group Co., Ltd. is a Chinese pharmaceutical company that focuses on the development, production, and sale of a broad range of medicinal products within China. Its offerings include both proprietary traditional Chinese medicines (TCMs) and various chemical products, such as finished preparations, raw materials, and other related chemical compounds. The company's portfolio of finished drugs targets several key therapeutic areas, including respiratory conditions (like cough and phlegm), kidney-related ailments, infectious diseases, cardiovascular issues, and digestive system disorders. Beyond finished medications, Teyi Pharmaceutical also supplies a variety of chemical raw materials and products; notable examples include aluminum magnesium carbonate, phenytoin, ferrous sulfate, glacial acetic acid, calcium chloride, sodium chloride, bismuth and citric acid series compounds, and zinc sulfate. Based in Taishan, China, the company underwent a name change in November 2016, transitioning from its previous identity as Guangdong Taicheng Pharmaceutical Co., Ltd. to its current name, Teyi Pharmaceutical Group Co., Ltd.
Key people
Danqing Xu
Chairman of the Board, General Manager · since 2018
Yanling Huang
Deputy General Manager · since 2015
Weicheng Wu
Deputy General Manager · since 2022
Songqing Xu
Vice Chairman of the Board, Deputy General Manager · since 2018
Rongjun Xu
Deputy General Manager · since 2025
Wenge Yan
Deputy General Manager · since 2024
Yongzhao Zhang
Deputy General Manager · since 2015
Ronghuang Xu
Executive Chairman of the Board, General Manager(Manager) · since 2025
Zilan Xu
Secretary of the Board · since 2025
Xiliang Chen
Chief Financial Officer, Secretary of the Board, Director · since 2018
Ruqing Yao
Staff Elected Director · since 2025
Hanqi Lai
Independent Director · since 2025
Independent Director · since 2015
Xiaobo Zhao
Independent Director · since 2025
Headquarters & legal address
台山市台城长兴路9、11号
江门市, GD 510000
CN
江门市, GD 510000
CN
Valuation
Title CNY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2022‑00 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | |||||||||||
Revenues | |||||||||||
Cost of revenue | |||||||||||
Unusual Expense (Income) | |||||||||||
NOPBT | |||||||||||
NOPBT Margin | |||||||||||
Operating Taxes | |||||||||||
Tax Rate | |||||||||||
NOPAT | |||||||||||
Net income | |||||||||||
Dividends | |||||||||||
Dividend yield | |||||||||||
Proceeds from repurchase of equity | |||||||||||
BB yield | |||||||||||
| Debt | |||||||||||
Debt current | |||||||||||
Long-term debt | |||||||||||
Deferred revenue | |||||||||||
Other long-term liabilities | |||||||||||
Net debt | |||||||||||
| Cash flow | |||||||||||
Cash from operating activities | |||||||||||
CAPEX | |||||||||||
Cash from investing activities | |||||||||||
Cash from financing activities | |||||||||||
FCF | |||||||||||
| Balance | |||||||||||
Cash | |||||||||||
Long term investments | |||||||||||
Excess cash | |||||||||||
Stockholders' equity | |||||||||||
Invested Capital | |||||||||||
ROIC | |||||||||||
ROCE | |||||||||||
| EV | |||||||||||
Common stock shares outstanding | |||||||||||
Price | |||||||||||
Market cap | |||||||||||
EV | |||||||||||
EBITDA | |||||||||||
EV/EBITDA | |||||||||||
Interest | |||||||||||
Interest/NOPBT | |||||||||||